Cargando…
Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer
BACKGROUND: ‘Flare phenomenon’ after initial luteinizing hormone-releasing hormone agonist administration is a widely approved concept in the treatment of prostate cancer. In most guidelines, concomitant therapy with anti-androgens is recommended to prevent this flare phenomenon. However, there are...
Autores principales: | Uehara, Sho, Yuasa, Takeshi, Fujii, Yasuhisa, Yano, Akihiro, Yamamoto, Shinya, Masuda, Hitoshi, Fukui, Iwao, Yonese, Junji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526290/ https://www.ncbi.nlm.nih.gov/pubmed/26242866 http://dx.doi.org/10.1186/s13104-015-1297-3 |
Ejemplares similares
-
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016) -
A case of gastric metastasis from renal cell cancer during the sequential targeted therapy
por: Uehara, Sho, et al.
Publicado: (2017) -
Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report
por: Sano, Masayuki, et al.
Publicado: (2016) -
Clinical outcome of patients with pancreatic metastases from renal cell cancer
por: Yuasa, Takeshi, et al.
Publicado: (2015) -
Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)